NO20090270L - Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister - Google Patents

Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister

Info

Publication number
NO20090270L
NO20090270L NO20090270A NO20090270A NO20090270L NO 20090270 L NO20090270 L NO 20090270L NO 20090270 A NO20090270 A NO 20090270A NO 20090270 A NO20090270 A NO 20090270A NO 20090270 L NO20090270 L NO 20090270L
Authority
NO
Norway
Prior art keywords
par
antagonists
cinnamoyl
halogen
piperazine derivatives
Prior art date
Application number
NO20090270A
Other languages
English (en)
Other versions
NO341389B1 (no
Inventor
Michel Perez
Marie Lamothe
Bruno Le Grand
Robert Letienne
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20090270L publication Critical patent/NO20090270L/no
Publication of NO341389B1 publication Critical patent/NO341389B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Den foreliggende oppfinnelsen angår forbindelser med den generelle formel (I) hvor Ri representerer halogen, CN eller NO2, R2 representerer hydrogen eller halogen; n representerer 1 eller 2; R3 representerer fenyl substituert med ett eller flere halogenatomer eller Ci-C6-alkylgruppeer; eller en sykloheksylgruppe; så vel som de farmasøytisk akseptable saltene og solvatene av disse. Disse forbindelsene kan brukes som proteaseaktiverte reseptor-1 (par-1) antagonister, da spesielt ved behandlingen av trombose.
NO20090270A 2006-06-19 2009-01-16 Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister NO341389B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605419A FR2902426B1 (fr) 2006-06-19 2006-06-19 Derives de cinnamoyl-piperazine
PCT/EP2007/056086 WO2007147824A1 (en) 2006-06-19 2007-06-19 Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Publications (2)

Publication Number Publication Date
NO20090270L true NO20090270L (no) 2009-03-03
NO341389B1 NO341389B1 (no) 2017-10-30

Family

ID=37846050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090270A NO341389B1 (no) 2006-06-19 2009-01-16 Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister

Country Status (32)

Country Link
US (2) US8217046B2 (no)
EP (1) EP2041104B1 (no)
JP (1) JP5356222B2 (no)
KR (1) KR101468752B1 (no)
CN (1) CN101472907B (no)
AR (1) AR061520A1 (no)
AT (1) ATE478059T1 (no)
AU (1) AU2007263051B2 (no)
BR (1) BRPI0713132B8 (no)
CA (1) CA2655527C (no)
CR (1) CR10509A (no)
DE (1) DE602007008572D1 (no)
EC (1) ECSP099065A (no)
ES (1) ES2349324T3 (no)
FR (1) FR2902426B1 (no)
GE (1) GEP20115201B (no)
HK (1) HK1127353A1 (no)
IL (1) IL195972A (no)
MA (1) MA30756B1 (no)
MX (1) MX2008016447A (no)
MY (1) MY144461A (no)
NO (1) NO341389B1 (no)
NZ (1) NZ573764A (no)
PL (1) PL2041104T3 (no)
PT (1) PT2041104E (no)
RU (1) RU2440997C2 (no)
SA (1) SA07280330B1 (no)
TN (1) TNSN08522A1 (no)
TW (1) TWI404710B (no)
UA (1) UA96947C2 (no)
WO (1) WO2007147824A1 (no)
ZA (1) ZA200900303B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3014693B1 (fr) * 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US10028999B2 (en) 2014-05-11 2018-07-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. PAR-1 based therapeutic conjugates and uses thereof
WO2016066789A1 (fr) * 2014-10-31 2016-05-06 Pierre Fabre Medicament Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN104529860B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含硝基苯和二烯氟代金刚烷结构的化合物及制备方法
CN104496924B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 卤苯二烯四氮唑类化合物、其制备方法和用途
CN104496922B (zh) * 2015-01-13 2016-04-06 佛山市赛维斯医药科技有限公司 腈基苯二烯四氮唑类化合物、其制备方法和用途
CN105949116A (zh) * 2016-06-08 2016-09-21 青岛理工大学 酰基哌嗪类化合物及其制备方法和用途
EP3278802A1 (en) 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
RU2662308C1 (ru) * 2017-12-25 2018-07-25 Феркат Адельзянович Халиуллин Средство для лечения и профилактики тромбоза
EP3787661B1 (en) 2018-05-02 2023-10-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Combination of temozolomide and a par-1 conjugate for treating glioblastoma
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
KR20230046343A (ko) * 2021-09-29 2023-04-06 주성수 피페론구민계 화합물을 유효성분으로 포함하는 혈관질환 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002076965A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Non peptide mimetics based on the active sequence s42fllr46 of the thrombin receptor for the treatment of thrombosis and cancer
CN1775762A (zh) * 2005-12-06 2006-05-24 山东大学 川芎嗪酰基哌嗪衍生物、制备方法和药物组合物与应用
FR2917622B1 (fr) * 2007-06-19 2009-10-23 Pierre Fabre Medicament Sa Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Also Published As

Publication number Publication date
ATE478059T1 (de) 2010-09-15
PL2041104T3 (pl) 2011-01-31
KR101468752B1 (ko) 2014-12-03
MA30756B1 (fr) 2009-10-01
EP2041104A1 (en) 2009-04-01
NO341389B1 (no) 2017-10-30
UA96947C2 (ru) 2011-12-26
FR2902426A1 (fr) 2007-12-21
FR2902426B1 (fr) 2008-09-05
MY144461A (en) 2011-09-30
BRPI0713132B8 (pt) 2021-05-25
PT2041104E (pt) 2010-11-08
IL195972A (en) 2014-05-28
JP5356222B2 (ja) 2013-12-04
CA2655527A1 (en) 2007-12-27
JP2009541260A (ja) 2009-11-26
CN101472907B (zh) 2012-08-29
AR061520A1 (es) 2008-09-03
RU2440997C2 (ru) 2012-01-27
AU2007263051B2 (en) 2011-10-20
ZA200900303B (en) 2009-12-30
CA2655527C (en) 2014-12-23
US8217046B2 (en) 2012-07-10
EP2041104B1 (en) 2010-08-18
TWI404710B (zh) 2013-08-11
CN101472907A (zh) 2009-07-01
CR10509A (es) 2009-02-05
RU2008152247A (ru) 2010-07-27
SA07280330B1 (ar) 2010-10-23
AU2007263051A1 (en) 2007-12-27
WO2007147824A1 (en) 2007-12-27
BRPI0713132B1 (pt) 2020-10-20
TNSN08522A1 (en) 2010-04-14
ES2349324T3 (es) 2010-12-30
HK1127353A1 (en) 2009-09-25
KR20090031572A (ko) 2009-03-26
IL195972A0 (en) 2009-09-01
GEP20115201B (en) 2011-04-11
NZ573764A (en) 2011-01-28
BRPI0713132A2 (pt) 2012-04-17
ECSP099065A (es) 2009-02-27
US20090176803A1 (en) 2009-07-09
DE602007008572D1 (de) 2010-09-30
US8513258B2 (en) 2013-08-20
US20120232097A1 (en) 2012-09-13
TW200808742A (en) 2008-02-16
MX2008016447A (es) 2009-01-22

Similar Documents

Publication Publication Date Title
NO20090270L (no) Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
GEP20125437B (en) New sulfonamide derivatives as bradykinin antagonists
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
TW200833324A (en) Sulfonamide derivatives
CY1113911T1 (el) Παραγωγα sf5 ως αναστολεις par1, η παρασκευη τους και η χρηση τους ως φαρμακα
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
NO20062533L (no) 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
UY29012A1 (es) "oxazolididonas y composiciones y metodos relacionados"
NO20064074L (no) Pyrrolokinolin- og piperidinokinolinderivater, fremstilling derav, sammensetninger inneholdende disse og anvendelse derav
NO20062307L (no) Spirofuropyridinarylderivater
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
NO20081529L (no) Naftyridinderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees